Relmada Therapeutics, Inc. RLMD Current ratio

Current ratio at other companies

Johnson & JohnsonJNJ

1.1×+0.1×

Merck & Co.MRK

1.3×-0.1×

Aardvark Therapeutics, Inc.AARD

8.1×-17.8×

CG OncologyCGON

22.2×+0.1×

Nuvectis Pharma, Inc.NVCT

2.3×-1.0×

ImmunomeIMNM

15.1×+3.0×

FAQ

What is Relmada Therapeutics, Inc.'s current ratio?

Relmada Therapeutics, Inc. (RLMD) reported current ratio of 18.3× in Q1 2026.

How has Relmada Therapeutics, Inc.'s current ratio changed year-over-year?

Relmada Therapeutics, Inc.'s current ratio increased by 245.3% year-over-year, from 5.3× to 18.3×.

What is the long-term trend for Relmada Therapeutics, Inc.'s current ratio?

Over 5 years (2020 to 2025), Relmada Therapeutics, Inc.'s current ratio has grown at a 9.3% compound annual growth rate (CAGR), from 9.4× to 14.6×.

What does current ratio mean?

Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.